Pirtobrutinib
Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM[1].
Product Specifications
CAS Number
[2101700-15-4]
Product Name Alternative
LOXO-305
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Btk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/btk-inhibitor-16.html
Purity
99.90
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(C1=C(N)N([C@@H](C)C(F)(F)F)N=C1C2=CC=C(CNC(C3=CC(F)=CC=C3OC)=O)C=C2)N
Molecular Formula
C22H21F4N5O3
Molecular Weight
479.43
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral human COL6A3 shRNA (UAS) - Lentiviral human COL6A3 shRNA (UAS, GFP) (25)
Mouse Monoclonal UCH-L1/PGP9.5 Antibody (13C4) [Alexa Fluor 594]
